Shopping Cart
- Remove All
- Your shopping cart is currently empty
Depatuxizumab, a brain-penetrant, humanized anti-EGFR monoclonal antibody, selectively inhibits the growth of mutant EGFRvIII and wild-type EGFR xenograft models, and is utilized for research on cancer [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Depatuxizumab, a brain-penetrant, humanized anti-EGFR monoclonal antibody, selectively inhibits the growth of mutant EGFRvIII and wild-type EGFR xenograft models, and is utilized for research on cancer [1]. |
In vivo | Depatuxizumab administered intraperitoneally (i.p.) at doses of 10 and 40 mg/kg three times per week for two weeks significantly inhibited tumor growth in the U87MG delta-2-7 glioblastoma (GBM) variant model and the A431 epidermoid carcinoma model in Nu/Nu mice [1]. The same treatment regimen with depatuxizumab suppressed tumor growth and levels of phosphorylated EGFR (pEGFR) in the EGFRvIII-positive GBM-SN0199-PDX model in NSG mice [1]. Moreover, depatuxizumab demonstrated dose-dependent inhibition of tumor growth in the SCC15 tumor-bearing SCID Beige mouse model when administered at concentrations ranging from 2 to 40 mg/kg [1]. |
Alias | ABT-806 |
Cas No. | 1471999-69-5 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.